Mutations in porin LamB contribute to ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae

被引:26
|
作者
Guo, Yingyi [1 ]
Liu, Ningjing [1 ]
Lin, Zhiwei [2 ]
Ba, Xiaoliang [3 ]
Zhuo, Chuyue [1 ]
Li, Feifeng [1 ]
Wang, Jiong [1 ]
Li, Yitan [2 ]
Yao, Likang [1 ]
Liu, Baomo [1 ]
Xiao, Shunian [1 ]
Jiang, Ying [1 ]
Zhuo, Chao [1 ]
机构
[1] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Hlth, Guangzhou, Peoples R China
[2] Peoples Hosp Yangjiang, Lab Resp Dis, Yangjiang, Guangdong, Peoples R China
[3] Univ Cambridge, Dept Vet Med, Cambridge, England
基金
中国国家自然科学基金;
关键词
Ceftazidime-avibactam; KPC; LamB; PBP3; expression level of bla (KPC); IN-VITRO ACTIVITY; ESCHERICHIA-COLI; MOLECULAR EPIDEMIOLOGY; ENTEROBACTERIACEAE; ACID;
D O I
10.1080/22221751.2021.1984182
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Ceftazidime-avibactam (CAZ-AVI) shows promising activity against carbapenem-resistant Klebsiella pneumoniae (CRKP), however, CAZ-AVI resistance have emerged recently. Mutations in KPCs, porins OmpK35 and/or OmpK36, and PBPs are known to contribute to the resistance to CAZ-AVI in CRKP. To identify novel CAZ-AVI resistance mechanism, we generated 10 CAZ-AVI-resistant strains from 14 CAZ-AVI susceptible KPC-producing K. pneumoniae (KPC-Kp) strains through in vitro multipassage resistance selection using low concentrations of CAZ-AVI. Comparative genomic analysis for the original and derived mutants identified CAZ-AVI resistance-associated mutations in KPCs, PBP3 (encoded by ftsI), and LamB, an outer membrane maltoporin. CAZ-AVI susceptible KPC-Kp strains became resistant when complemented with mutated bla (KPC) genes. Complementation experiments also showed that a plasmid borne copy of wild-type lamB or ftsI gene reduced the MIC value of CAZ-AVI in the induced resistant strains. In addition, bla (KPC) expression level increased in four of the six CAZ-AVI-resistant strains without KPC mutations, indicating a probable association between increased bla (KPC) expression and increased resistance in these strains. In conclusion, we here identified a novel mechanism of CAZ-AVI resistance associated with mutations in porin LamB in KPC-Kp.
引用
收藏
页码:2042 / 2051
页数:10
相关论文
共 50 条
  • [41] In vitro activity of ceftazidime/avibactam against KPC-producing Klebsiella pneumoniae in Greece: A single-centre study
    Protonotariou, Efthymia
    Meletis, Georgios
    Kachrimanidou, Melania
    Papadopoulou, Dimitra
    Stamou, Aikaterini
    Arhonti, Maria
    Skoura, Lemonia
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2020, 20 : 82 - 83
  • [43] Ceftazidime-avibactam susceptible to resistant KPC-producing Enterobacterales bloodstream infections: an observational study
    Iannaccone, Marco
    Boattini, Matteo
    Bianco, Gabriele
    Corcione, Silvia
    Cavallo, Rossana
    Costa, Cristina
    JOURNAL OF CHEMOTHERAPY, 2020, 32 (03) : 160 - 162
  • [44] In Vitro Evaluation of Increasing Avibactam Concentrations on Ceftazidime Activity against Ceftazidime/Avibactam-Susceptible and Resistant KPC-Producing Klebsiella pneumoniae Clinical Isolates
    Palombo, Marta
    Secci, Benedetta
    Bovo, Federica
    Gatti, Milo
    Ambretti, Simone
    Gaibani, Paolo
    ANTIBIOTICS-BASEL, 2023, 12 (12):
  • [45] Prevalence and mortality of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae bloodstream infections (2018-2022)
    Boattini, Matteo
    Bianco, Gabriele
    Bastos, Paulo
    Comini, Sara
    Corcione, Silvia
    Almeida, Andre
    Costa, Cristina
    De Rosa, Francesco Giuseppe
    Cavallo, Rossana
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2024, 43 (01) : 155 - 166
  • [46] Rapid diagnostics and ceftazidime/avibactam for KPC-producing Klebsiella pneumoniae bloodstream infections: impact on mortality and role of combination therapy
    Boattini, Matteo
    Bianco, Gabriele
    Charrier, Lorena
    Comini, Sara
    Iannaccone, Marco
    Almeida, Andre
    Cavallo, Rossana
    De Rosa, Francesco Giuseppe
    Costa, Cristina
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2023, 42 (04) : 431 - 439
  • [47] Rapid diagnostics and ceftazidime/avibactam for KPC-producing Klebsiella pneumoniae bloodstream infections: impact on mortality and role of combination therapy
    Matteo Boattini
    Gabriele Bianco
    Lorena Charrier
    Sara Comini
    Marco Iannaccone
    André Almeida
    Rossana Cavallo
    Francesco Giuseppe De Rosa
    Cristina Costa
    European Journal of Clinical Microbiology & Infectious Diseases, 2023, 42 : 431 - 439
  • [48] Using Therapeutic Drug Monitoring to Treat KPC-Producing Klebsiella pneumoniae Central Nervous System Infection With Ceftazidime/Avibactam
    Yasmin, Mohamad
    Hanrahan, Jennifer
    Marshall, Steven
    Lodise, Thomas P.
    Chen, Liang
    Perez, Federico
    Kreiswirth, Barry
    Bonomo, Robert A.
    OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (09):
  • [49] KPC-39-Mediated Resistance to Ceftazidime-Avibactam in a Klebsiella pneumoniae ST307 Clinical Isolate
    Jousset, Agnes B.
    Oueslati, Saoussen
    Emeraud, Cecile
    Bonnin, Remy A.
    Dortet, Laurent
    Iorga, Bogdan I.
    Naas, Thierry
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (12)
  • [50] Ceftazidime/Avibactam Resistance in Carbapenemase-Producing Klebsiella pneumoniae
    Cui, Qiaozhen
    Wang, Chen
    Wang, Qichen
    Qin, Juanxiu
    Li, Min
    Ding, Baixing
    Shen, Zhen
    EMERGING INFECTIOUS DISEASES, 2023, 29 (11) : 2398 - 2400